OR WAIT null SECS
© 2025 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology® spoke with Will Gordon, senior vice president of Product Management, ArisGlobal, about how the geopolitical instabilities might impact the bio/pharmaceutical industry.
Diversifying where a company sources ingredients and products is an important part of keeping the supply chain robust, says Will Gordon, senior vice president of Product Management, ArisGlobal, and companies must be able to adapt to geopolitical instability to continue to secure the supply chain.
“If something happens in X country, are you able to quickly shift capacity to develop whatever it is to another country or another area? And if we look at what's happening in the United States, there's this BIOSECURE Act, and that's kind of similar, right? So, the US government could, at any point say, ‘Okay, this company is associated to this government, and they're a non-friendly government, and so we're no longer going to allow you to source products from that if you have any federal funds.’ Well, most pharmaceutical companies receive federal funds because government is a large purchaser of pharmaceutical product, right? So, you have to be able to say, okay, how can we shift capacity? How can we shift our supply chains? And I think the pharmaceutical companies of the world have done a really good job at creating that robustness across the supply chain, from sourcing all the way to delivery, and they just have to continue to be nimble and shift as political changes come up,” says Gordon.
Click the video above to watch the full interview.
Will Gordon is senior vice president of Product Management, ArisGlobal.